Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 o Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (IRS ...

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +566.67%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.24, delivering a surprise of +700%.Over the last four quarters, the company ...

OptimizeRx (NasdaqCM:OPRX) Q3 2025 Earnings Call November 06, 2025 04:30 PM ET Speaker0The Street and also to our clients and investors that we're going to give more visibility on our visibility into the future as we've been migrating more toward a predictive model. We've quoted in the past descriptive momentum. So we're going to continue to push that throughout the remainder of the year. And as a result of that, we're now getting more visibility into the out years, including 2026. In terms of the RFP situa ...

million and $22 million OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance - Q3 revenue of $26.1 million, increased 22% year-over-year - Q3 gross profit increased 30% year-over-year to $17.5 million Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million - Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range bet ...

-   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan subsequent to ...

公司财务信息发布安排 - 公司将于2025年11月6日美国东部时间下午4点30分举行电话会议，讨论截至2025年9月30日的第三季度业绩 [1] - 财务业绩公告将在电话会议前通过新闻稿发布 [1] 公司业务与战略定位 - 公司是一家领先的医疗保健技术解决方案提供商，帮助生命科学公司触达和参与医疗保健专业人士及患者 [1][4] - 公司平台结合了人工智能驱动的工具，如动态受众激活平台和微区域定位，以提供及时、相关和超本地化的互动 [4] - 公司致力于通过连接医疗保健专业人士和直接面向消费者的策略，为品牌创造同步的营销解决方案，以加速治疗决策和改善患者预后 [4] - 公司总部位于马萨诸塞州沃尔瑟姆，与全球领先的制药和生命科学公司合作 [5]

Many people see OptimizeRx Corporation (NASDAQ: OPRX ) as a simple message platform inside Electronic Health Record (EHR) Systems or an intermediary that connects pharma companies with doctors. Our thesis says that OPRX transforms itself from just a delivery channel to a clinical dataAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or s ...

Many people see OptimizeRx Corporation (NASDAQ: OPRX ) as a simple message platform inside Electronic Health Record (EHR) Systems or an intermediary that connects pharma companies with doctors. Our thesis says that OPRX transforms itself from just a delivery channelAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

OptimizeRx (OPRX) 2025年第二季度业绩表现 - 第二季度收入达2920万美元，同比增长55%，每股收益为24美分，均大幅超出市场一致预期[1] - 调整后息税折旧摊销前利润为580万美元，毛利率持续扩大，显示运营杠杆效应[1] - 管理层将全年收入指引上调至1.04亿至1.08亿美元，已签约收入增长超过30%，表明客户信心增强[1] OptimizeRx (OPRX) 战略与运营 - 公司核心战略为人工智能驱动的工作流程整合，其全渠道平台通过DAAP等工具和微区域定位技术，重塑数字医药营销[2] - 在监管不确定性和转向专科药物的行业背景下，公司技术栈的可扩展性显著，营收两位数增长的同时运营费用保持平稳[3] - 来自顶级20家制药制造商的平均收入提升至310万美元，中层客户规模增速快于顶级客户，客户基础拓宽[5] 行业竞争格局与同行动态 - Omnicell (OMCL) 通过其Intelligence-Enabled Pharmacy愿景强化数字健康战略，推广基于云和人工智能的OmniSphere平台[6] - OMCL的Advanced Services套件整合自动化、分析和远程药房服务，旨在优化医疗机构的临床和财务结果[7] - Teladoc Health (TDOC) 重点发展数字心理健康，通过BetterHelp平台和收购UpLift提供网络内治疗选项，UpLift网络拥有超过1500名持证专业人士[8] - Teladoc投资于人工智能临床文档工具和Prism护理交付平台，以增强虚拟护理生态系统的整合[9]